Compare Merck & Co., Inc. (MRK) vs Ferrari NV (RACE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Merck & Co., Inc. vs Ferrari NV — how do they compare? Merck & Co., Inc. trades at $126.24 (market cap $307.25B), while Ferrari NV trades at $370.05 (market cap $65.48B). The key difference: Merck & Co., Inc. is far larger — about 4.7× Ferrari NV's market cap, and Merck & Co., Inc. pays the higher dividend (2.73%). Which is the better fit depends on your goals.
| MRK | RACE | |
|---|---|---|
Market Cap | $307.25B | $65.48B |
Sector | Health | Consumer Cyclical |
52-Week High | $129.52 | $517.65 |
52-Week Low | $77.60 | $314.63 |
Enterprise Value | $350.66B | $66.69B |
Dividend Yield | 2.73% | 1.14% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Merck (MRK) trades at $126.27, down 0.96% on the day, with a neutral technical signal and strong fundamental performance. The company reported robust 2025 results with $65.01B revenue and $18.25B net income, beating EPS estimates in recent quarters. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, while analyst consensus remains bullish with a $137.30 price target.
Outlook is positive driven by earnings momentum and strategic M&A, but risks include patent expirations and competitive pressures. The stock offers a dividend yield with upcoming payment, supporting income investors. Valuation multiples are elevated, requiring sustained growth to justify current levels amid macroeconomic uncertainties.
Ferrari (RACE) trades at $369.97, down 1.82% today, with a bullish technical outlook supported by moving averages and key support at $370. The company demonstrates strong fundamentals with consistent earnings beats, a 22.19% net margin, and robust cash flow from operations of $2.35B in 2025. Recent news highlights ongoing share buybacks and the upcoming Q2 2026 earnings report on July 30.
The investment outlook remains positive given Ferrari's premium brand positioning, pricing power, and analyst consensus price target of $467.50 implying 26% upside. Risks include execution challenges with new EV models, economic sensitivity, and high valuation multiples. Wall Street sentiment is strongly bullish with 72% buy ratings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →About Ferrari NV
Ferrari engineers and manufactures some of the world's most expensive exotic sports cars. The Ferrari brand is synonymous with Formula One racing, exclusivity, Italian design, and state-of-the-art technology. Ferrari also has a captive finance company that provides funding for dealers and clients.
Read more on RACE →
